Extinction of influenza B Yamagata: Its impact on public health and vaccine implications

References

[1] Virk RK, Jayakumar J, Mendenhall IH, et al. Divergent evolutionary trajectories of influenza B viruses underlie their contemporaneous epidemic activity[J]. Proc Natl Acad Sci U S A, 2020, 117(1): 619-628. doi: 10.1073/pnas.1916585116

[2] Zanobini P, Bonaccorsi G, Lorini C, et al. Global patterns of seasonal influenza activity, duration of activity and virus (sub) type circulation from 2010 to 2020[J]. Influenza Other Respir Viruses, 2022, 16(4): 696-706. doi: 10.1111/irv.12969

[3] Wong PF, Isakova-Sivak I, Stepanova E, et al. Development of cross-reactive live attenuated influenza vaccine candidates against both lineages of influenza B virus[J]. Vaccines, 2024, 12(1): 95. doi: 10.3390/vaccines12010095

[4] Isakova-Sivak I, Grigorieva E, Rudenko L. Insights into current clinical research on the immunogenicity of live attenuated influenza vaccines[J]. Expert Rev Vaccines, 2020, 19(1): 43-55. doi: 10.1080/14760584.2020.1711056

[5] Dhanasekaran V, Sullivan S, Edwards KM, et al. Human seasonal influenza under COVID-19 and the potential consequences of influenza lineage elimination[J]. Nat Commun, 2022, 13(1): 1721. doi: 10.1038/s41467-022-29402-5

[6] Koutsakos M, Wheatley AK, Laurie K, et al. Influenza lineage extinction during the COVID-19 pandemic?[J]. Nat Rev Microbiol, 2021, 19(12): 741-742. doi: 10.1038/s41579-021-00642-4

[7] Paget J, Caini S, Del Riccio M, et al. Has influenza B/Yamagata become extinct and what implications might this have for quadrivalent influenza vaccines?[J]. Eurosurveillance, 2022, 27(39): 2200753. https://pubmed.ncbi.nlm.nih.gov/36177871/

[8] Xu CL, Chan KH, Tsang TK, et al. Comparative epidemiology of influenza B Yamagata-and Victoria-lineage viruses in households[J]. Am J Epidemiol, 2015, 182(8): 705-713. doi: 10.1093/aje/kwv110

[9] Dudas G, Bedford T, Lycett S, et al. Reassortment between influenza B lineages and the emergence of a coadapted PB1-PB2-HA gene complex[J]. Mol Biol Evol, 2015, 32(1): 162-172. doi: 10.1093/molbev/msu287

[10] Vesikari T, Karvonen A, Korhonen T, et al. A randomized, double-blind study of the safety, transmissibility and phenotypic and genotypic stability of cold-adapted influenza virus vaccine[J]. Pediatr Infect Dis J, 2006, 25(7): 590-595. doi: 10.1097/01.inf.0000220229.51531.47

[11] Fallani E. Public health impact of influenza vaccination in Italy: barriers, benefits and interventions in the field of prevention[EB/OL]. [2024-05-01]. https://usiena-air.unisi.it/handle/11365/1252294

[12] 2024 WHoWFGIPGWAA[EB/OL]. [2024-05-01]. https://www.who.int/tools/flunet.

[13] GISAID[EB/OL]. [2024-05-01]. https://gisaid.org/.

[14] Caini S, Stolyarov K, Sominina A, et al. A comparative analysis of the epidemiology of influenza and respiratory syncytial virus in Russia, 2013/14 to 2018/19[J]. J Glob Health, 2022, 12: 04009. doi: 10.7189/jogh.12.04009

[15] World Health Organization. Influenza (Seasonal)[EB/OL]. [2024-05-01]. https://www.who.int/en/news-room/fact-sheets/detail/influenza-(seasonal).

[16] Bonacina F, Boëlle PY, Colizza V, et al. Global patterns and drivers of influenza decline during the COVID-19 pandemic[J]. Int J Infect Dis, 2023, 128: 132-139. doi: 10.1016/j.ijid.2022.12.042

[17] Curran T, McCaughey C, Ellis J, et al. False-positive PCR results linked to administration of seasonal influenza vaccine[J]. J Med Microbiol, 2012, 61(3): 332-338. doi: 10.1099/jmm.0.036178-0

[18] Merced-Morales A, Daly P, Elal AIA, et al. Influenza activity and composition of the 2022-23 influenza vaccine—United States, 2021-22 season[J]. MMWR Morb Mortal Wkly Rep, 2022, 71(29): 913-919. doi: 10.15585/mmwr.mm7129a1